Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million?fool.comPaymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries.
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million?fool.comAmprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets.
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors?fool.comSkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investmentfool.comViking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Dropfool.comThis biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Millionfool.comNurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%fool.comThis clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Yearfool.comThis clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025fool.comKrystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%fool.comScholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimismstocktwits.comJefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday.
Got $300? 2 Biotech Stocks to Buy and Hold Foreverfool.comThese two biotechs only have one marketable therapy each, but both have blockbuster potential.
Soleus Adds a Significant Number of Celcuity Sharesfool.comThis clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Dropfool.comThe timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention.
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm?fool.comA sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility.
